COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS]) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545 · cited 2×
“Highly cytotoxic CD8+ T cells may explain immune-mediated tissue damage (7), and functionally exhausted T cells highly expressing inhibitory fac-”
BackgroundSex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370
COVID-19 and Italy: what next?
Remuzzi, A., & Remuzzi, G. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30627-9 · Cited by 3,119
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 1×
“One of the key mediators of autoimmunity, inflammation (48), viral cytokine storms, and CRSinduced damage is IL-6 (49).”
BackgroundEffective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,008
Coronavirus infections and immune responses
Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25685 · Cited by 1,946
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Richardson, P., Griffin, I., Tucker, C., Smith, D., Oechsle, O., Phelan, A., Rawling, M., Savory, E., & Stebbing, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30304-4 · Cited by 1,456
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
Clinical Characteristics of Coronavirus Disease 2019 in China
Eastin, C., & Eastin, T. (2020) · The Journal of Emergency Medicine · doi:10.1016/j.jemermed.2020.04.004 · Cited by 1,234
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217 · cited 3×
“They can suppress the exuberant systemic inflammatory response associated with ARDS (66), but there is no evidence that they lead to a clinical improvement in patients with viral interstitial pneumonia, particularly SARS, MERS and H1N1 (25, 64, 65-68), and they may even exacerbate lung injury (69).”
BackgroundCorticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
Arabi, Y. M., Mandourah, Y., Al-Hameed, F., Sindi, A. A., Almekhlafi, G. A., Hussein, M. A., Jose, J., Pinto, R., Al-Omari, A., Kharaba, A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1172oc · Cited by 1,122
COVID-19: combining antiviral and anti-inflammatory treatments
Stebbing, J., Phelan, A., Griffin, I., Tucker, C., Oechsle, O., Smith, D., & Richardson, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30132-8 · Cited by 1,117 · cited 2×
“It may therefore be useful in the treatment and prevention of the cytokine dysregulation associated with COVID-19 (43, 44) as it could affect the host inflammatory response and viral entry into cells.”
BackgroundChen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., Men, D., Huang, Q., Liu, Y., Yang, B., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa449 · Cited by 1,020
Chan, J. F. W., Lau, S. K. P., To, K. K. W., Cheng, V. C. C., Woo, P. C. Y., & Yuen, K.-Y. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 881
Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2
Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., & Zuo, W. (2020) · doi:10.1101/2020.01.26.919985 · Cited by 860 · cited 2×
“Interestingly, ACE2 receptors are not only expressed on alveolar epithelial type II cells (4), which represent 83% of all ACE2-expressing cells, but also on heart, kidney, endothelium, and gut cells (5).”
BackgroundLiu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830 · cited 1×
“the rapid viral replication causing cell apoptosis may lead to the massive release of inflammatory mediators) (29), and others have underlined the importance of antibodies against spike protein (anti-S-IgG) as promoters of pro-inflammatory monocyte/ macrophage accumulation in the lungs (30).”
BackgroundFu, Y., Cheng, Y., & Wu, Y. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00207-4 · Cited by 788
Sex difference and smoking predisposition in patients with COVID-19
Cai, H. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30117-x · Cited by 625
Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases
Antonelli, A., Ferrari, S. M., Giuggioli, D., Ferrannini, E., Ferri, C., & Fallahi, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.010 · Cited by 595 · cited 1×
“They have also been putatively implicated in the development of immune-driven diseases (16).”
BackgroundNew insights into the antiviral effects of chloroquine
Savarino, A., Di Trani, L., Donatelli, I., Cauda, R., & Cassone, A. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70361-9 · Cited by 570
Wan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., Lang, C., Xiao, Q., Xiao, K., Yi, Z., et al. (2020) · doi:10.1101/2020.02.10.20021832 · Cited by 562
Haga, S., Yamamoto, N., Nakai-Murakami, C., Osawa, Y., Tokunaga, K., Sata, T., Yamamoto, N., Sasazuki, T., & Ishizaka, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711241105 · Cited by 521
Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells
Law, H. K. W., Cheung, C. Y., Ng, H. Y., Sia, S. F., Chan, Y. O., Luk, W., Nicholls, J. M., Peiris, J. S. M., & Lau, Y. L. (2005) · Blood · doi:10.1182/blood-2004-10-4166 · Cited by 471
Pathology of fatal human infection associated with avian influenza A H5N1 virus
To, K.-F., Chan, P. K. S., Chan, K.-F., Lee, W.-K., Lam, W.-Y., Wong, K.-F., Tang, N. L. S., Tsang, D. N. C., Sung, R. Y. T., Buckley, T. A., et al. (2001) · Journal of Medical Virology · doi:10.1002/1096-9071(200103)63:3<242::aid-jmv1007>3.0.co;2-n · Cited by 424
Interleukin-6 as a key player in systemic inflammation and joint destruction
Fonseca, J. E., Santos, M. J., Canhão, H., & Choy, E. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.01.012 · Cited by 375
Yan, Y., Zou, Z., Sun, Y., Li, X., Xu, K.-F., Wei, Y., Jin, N., & Jiang, C. (2013) · Cell Research · doi:10.1038/cr.2012.165 · Cited by 353
Analysis of Serum Cytokines in Patients with Severe Acute Respiratory Syndrome
Zhang, Y., Li, J., Zhan, Y., Wu, L., Yu, X., Zhang, W., Ye, L., Xu, S., Sun, R., Wang, Y., et al. (2004) · Infection and Immunity · doi:10.1128/iai.72.8.4410-4415.2004 · Cited by 338
Yoshikawa, T., Hill, T., Li, K., Peters, C. J., & Tseng, C.-T. K. (2009) · Journal of Virology · doi:10.1128/jvi.01792-08 · Cited by 293
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
Wang, Z., & Han, W. (2018) · Biomarker Research · doi:10.1186/s40364-018-0116-0 · Cited by 273
Khanna, D., Denton, C. P., Lin, C. J. F., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211682 · Cited by 265 · cited 1×
“The off-label use of tocilizumab in the interstitial lung disease (ILD) caused by rheumatological diseases has been widely studied and is approved in many countries (54-58).”
BackgroundDe Lauretis, A., Sestini, P., Pantelidis, P., Hoyles, R., Hansell, D. M., Goh, N. S. L., Zappala, C. J., Visca, D., Maher, T. M., Denton, C. P., et al. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120725 · Cited by 263
Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?
Faure, E., Poissy, J., Goffard, A., Fournier, C., Kipnis, E., Titecat, M., Bortolotti, P., Martinez, L., Dubucquoi, S., Dessein, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088716 · Cited by 248
Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
Zhou, W., Liu, Y., Tian, D., Wang, C., Wang, S., Cheng, J., Hu, M., Fang, M., & Gao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0127-9 · Cited by 234
Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection
Yang, M. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3527420 · Cited by 200
[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
(2020) · PubMed · doi:10.3760/cma.j.issn.1001-0939.2020.0019 · Cited by 189
Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
Okabayashi, T., Kariwa, H., Yokota, S.-I., Iki, S., Indoh, T., Yokosawa, N., Takashima, I., Tsutsumi, H., & Fujii, N. (2006) · Journal of Medical Virology · doi:10.1002/jmv.20556 · Cited by 147
Overview of the biology of type I interferons
Kalliolias, G. D., & Ivashkiv, L. B. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2881 · Cited by 131
Systemic rheumatic diseases: From biological agents to small molecules
Sarzi‐Puttini, P., Ceribelli, A., Marotto, D., Batticciotto, A., & Atzeni, F. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.12.009 · Cited by 101
Self-citationMechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
Dholaria, B., Bachmeier, C. A., & Locke, F. L. (2018) · BioDrugs · doi:10.1007/s40259-018-0324-z · Cited by 85
Immunological responses against SARS-coronavirus infection in humans.
XiaojunXu, & Xiao-MingGao (2004) · PubMed · Cited by 81
Hui, D. S. C. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2371ed · Cited by 81
Channappanavar, R., Fehr, A. R., Vijay, R., Jincun, Z., Meyerholz, D. K., & Perlman, S. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.196.supp.63.10 · Cited by 79
Jiang, Y., Li, J., Teng, Y., Sun, H. C., Tian, G., He, L., Li, P., Chen, Y., Guo, Y., Li, J., et al. (2019) · Viruses · doi:10.3390/v11010039 · Cited by 78
Shieh, J., Tseng, H., Jung, F., Yang, S., & Lin, J. (2019) · Mediators of Inflammation · doi:10.1155/2019/7947596 · Cited by 74
How the SARS coronavirus causes disease: host or organism?
Lo, A. W., Tang, N. L., & To, K. (2006) · The Journal of Pathology · doi:10.1002/path.1897 · Cited by 55
Regulation of interferon production as a potential strategy for COVID-19 treatmentPreprint
Deng, X., Yu, X., & Pei, J. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2003.00751 · Cited by 26
Narváez, J., Lluch, J., Sancho, J. J. A., Molina‐Molina, M., Solé, J. M. N., & Castellvi, I. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214449 · Cited by 24
Cited by
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment
Soy, M., Keser, G., Atagündüz, P., Tabak, F., Atagündüz, I., & Kayhan, S. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05190-5 · Cited by 811
Comprehensive mapping of immune perturbations associated with severe COVID-19
Kuri-Cervantes, L., Pampena, M. B., Meng, W., Rosenfeld, A. M., Ittner, C. A. G., Weisman, A. R., Agyekum, R. S., Mathew, D., Baxter, A. E., Vella, L. A., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd7114 · Cited by 723
Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
Zhang, J.-J., Dong, X., Liu, G.-H., & Gao, Y.-D. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08921-5 · Cited by 715
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Metadata
- Authors
- Sarzi-Puttini, P., Giorgi, V., Sirotti, S., Marotto, D., Ardizzone, S., Rizzardini, G., Antinori, S., & Galli, M.
- Venue
- Clinical and Experimental Rheumatology
- Published
- 2020-03-26
- Volume
- 38
- Issue
- 2
- Pages
- 337-342
- ISSN
- 0392-856X (ISSN-L)
- 1593-098X
- OpenAlex
- W3012721127
- Cited by
- 466
- References
- 58
- FWCI
- 13.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.